Myint K, Sahoo S, Thein A, Moe S, Ni H
Cochrane Database Syst Rev. 2022; 12:CD010790.
PMID: 36508693
PMC: 9744465.
DOI: 10.1002/14651858.CD010790.pub3.
Khansari M, Garvey S, Farzad S, Shi Y, Shahidi M
Int J Retina Vitreous. 2019; 5:47.
PMID: 31832241
PMC: 6859621.
DOI: 10.1186/s40942-019-0198-3.
Gupta K, Chen C, Lutty G, Hebbel R
Blood Adv. 2019; 3(7):1073-1083.
PMID: 30944099
PMC: 6457224.
DOI: 10.1182/bloodadvances.2018026898.
Walkden A, Griffin B, Cheng C, Dhawahir-Scala F
BMJ Case Rep. 2019; 12(1).
PMID: 30700461
PMC: 6352801.
DOI: 10.1136/bcr-2018-227541.
Jee K, Rodrigues M, Kashiwabuchi F, Applewhite B, Han I, Lutty G
PLoS One. 2017; 12(8):e0183320.
PMID: 28832635
PMC: 5568377.
DOI: 10.1371/journal.pone.0183320.
Laser therapy for retinopathy in sickle cell disease.
Myint K, Sahoo S, Thein A, Moe S, Ni H
Cochrane Database Syst Rev. 2015; (10):CD010790.
PMID: 26451693
PMC: 8741205.
DOI: 10.1002/14651858.CD010790.pub2.
Intravitreal Ranibizumab for Stage IV Proliferative Sickle Cell Retinopathy: A First Case Report.
Mitropoulos P, Chatziralli I, Parikakis E, Peponis V, Amariotakis G, Moschos M
Case Rep Ophthalmol Med. 2014; 2014:682583.
PMID: 25506450
PMC: 4258923.
DOI: 10.1155/2014/682583.
Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.
Ballas S, Kesen M, Goldberg M, Lutty G, Dampier C, Osunkwo I
ScientificWorldJournal. 2012; 2012:949535.
PMID: 22924029
PMC: 3415156.
DOI: 10.1100/2012/949535.
Antiangiogenic therapy for ischemic retinopathies.
Al-Latayfeh M, Silva P, Sun J, Aiello L
Cold Spring Harb Perspect Med. 2012; 2(6):a006411.
PMID: 22675660
PMC: 3367538.
DOI: 10.1101/cshperspect.a006411.
Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy.
Babalola O
BMJ Case Rep. 2012; 2010.
PMID: 22461855
PMC: 3029455.
DOI: 10.1136/bcr.11.2009.2441.
Hemoglobin AC retinopathy managed with vitrectomy and adjunctive bevacizumab.
Pokroy R, Desai U
Eye (Lond). 2011; 25(11):1514-5.
PMID: 21818134
PMC: 3213652.
DOI: 10.1038/eye.2011.189.
Intravitreal bevacizumab: an analysis of the evidence.
Smit D, Meyer D
Clin Ophthalmol. 2009; 1(3):273-84.
PMID: 19668481
PMC: 2701127.
Effect of multiple injections of small divided doses vs single injection of intravitreal bevacizumab on retinal neovascular model in rabbits.
Saati S, Agrawal R, Louie S, Chader G, Humayun M
Graefes Arch Clin Exp Ophthalmol. 2009; 248(4):457-66.
PMID: 19644699
PMC: 2885282.
DOI: 10.1007/s00417-009-1153-z.
Role of intravitreal bevacizumab in the management of Eales' disease.
Chanana B, Azad R, Patwardhan S
Int Ophthalmol. 2009; 30(1):57-61.
PMID: 19165424
DOI: 10.1007/s10792-009-9292-0.
Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy.
Shaikh S
Indian J Ophthalmol. 2008; 56(3):259.
PMID: 18417840
PMC: 2636113.
DOI: 10.4103/0301-4738.40380.
